Ceftazidime-avibactam

ABSTRACT

The increase in nosocomial infections by beta-lactamaseproducing Gram-negative bacilli constitutes a therapeuticchallenge. The combination of ceftazidime-avibactam offers avery interesting therapeutic option for nosocomial pneumoniacaused by extended-spectrum beta-lactamase-producingKlebsiella pneumoniae, multidrug-resistant Pseudomonasaeruginosa, and other enterobacteria. Compared to carbapenems,ceftazidime-avibactam has demonstrated non-inferiority in thetreatment of nosocomial pneumonia including better clinical andmicrobiological cure rates and mortality compared to colistin. Thelimitation of ceftazidime-avibactam in the treatment of infectionscaused by metallo-beta-lactamase-producing Enterobacteriaceaecan be overcome with the addition of aztreonam (AU)